Lupin Pharmaceuticals, Inc. (LPI), a wholly owned subsidiary of Lupin, has entered into a settlement agreement to resolve civil litigation regarding generic pharmaceutical antitrust allegations. The company has agreed to a payment of USD 30 million to Humana Inc. to secure a full release of claims. Notably, this amount has already been accounted for in the company’s prior consolidated financial results, and the agreement includes no admission of liability or wrongdoing.
Resolution of Legal Proceedings
Lupin Pharmaceuticals, Inc. (LPI) has reached a definitive settlement with Humana Inc. to conclude civil lawsuits related to the In Re Generic Pharmaceuticals Antitrust Litigation. While the company maintains its denial of all allegations of anticompetitive behavior, the decision to settle was driven by a desire to avoid the ongoing costs and inherent uncertainties associated with continued legal proceedings.
Financial Impact and Terms
Under the terms of the settlement, LPI will pay USD 30 million to Humana Inc. This payment provides a full and final release of all claims against LPI, as well as its current and former parents, affiliates, directors, officers, and employees. The company has confirmed that the financial impact of this settlement has already been provisioned in its previous consolidated financial statements, ensuring no further surprise to the balance sheet.
No Admission of Liability
It is important to note that the agreement explicitly states that the settlement does not constitute an admission of liability or unlawful conduct by LPI. The company continues to refute the allegations but has opted for this resolution to mitigate risk and resolve its involvement in the broader collection of similar cases centered in Philadelphia, Pennsylvania.
Source: BSE
